The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
New study led by the University of Oxford has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more.
Of the 381 persistent infections, 65 had three or more PCR tests taken over the course of their infection. Most (82%) of these individuals demonstrated rebounding viral dynamics, experiencing high, then low, then high viral load dynamics. According to the researchers, this demonstrates that the virus can maintain the ability to actively replicate during prolonged infections.
Certain individuals showed an extremely high number of mutations, including mutations that define new coronavirus variants, alter target sites for monoclonal antibodies, and introduce changes to the coronavirus spike protein.
https://www.nature.com/articles/s41586-024-07029-4
Maria Van Kerkhove - WHO’s Department of Epidemic and Pandemic Preparedness and Prevention
How would you describe the overall state of COVID at this point in the pandemic?
“COVID’s not in the news every day, but it’s still a global health risk. If we look at wastewater estimates, the actual circulation [of SARS-CoV-2] is somewhere between two and 20 times higher than what’s actually being reported by countries. The virus is rampant. We’re still in a pandemic. There’s a lot of complacency at the individual level, and more concerning to me is that at the government level”
Do we believe the worlds leading scientists
Or
Tommoclarke who says it’s all over but spends his days on a chat board for Covid drugs he obviously doesn’t think are needed .
If we talking about bizarre that really is a bizarre thing to be doing
Highlighting a key piece of information in a study you posted saying twice as many paxlovid patients were vaccinated isn’t mud slinging
Quoting World Health Organisation figures isn’t mud slinging.
You do like to over exaggerate Doc D.
Apparently medical science doesn’t agree with you tommockarke
Southampton researchers are investigating if promising COVID-19 treatments can help other hospital patients and ease NHS winter pressures.
The ACCORD trial, led by Prof Tom Wilkinson, was set up during the height of the pandemic. The aim was to accelerate the development of new drugs for patients hospitalised with COVID-19.
Now, promising medicines from this trial are being tested as treatments for patients hospitalised with other lung conditions. If successful, these could greatly reduce NHS winter pressures.
Identifying new treatments
Respiratory diseases affect one in five people in the UK and are the third biggest cause of death in England. They are a major contributor to the winter pressures faced by the NHS.
Two of the three drugs tested in the ACCORD trial – tozorakimab and bemcentinib – have shown promise as treatments for patients with COVID-19 and are now progressing to larger trials.
These have the potential to help patients hospitalised with other lung infections. Tozorakimab, for example, targets a protein that is raised in many different respiratory infections.
Helping more patients
Prof Wilkinson leads the respiratory and allergy theme at the NIHR Southampton Biomedical Research Centre. He is Professor of Respiratory Medicine and Associate Dean for Enterprise at the University of Southampton.
He is now leading the UNIVERSAL study. This is harnessing advances in testing to identify and monitor people hospitalised with a viral respiratory infection. It aims to better understand how and when viral infections in the lungs and airways get worse, and develop effective antiviral treatments.
Alongside this, he is jointly leading the TILIA study, which aims to test the efficacy and safety of tozorakimab in hospital patients with viral lung infections who require oxygen.
The ACCORD trials platform runs in close alliance with a national collaboration of Phase 2 drug development platforms: CATALYST, DEFINE, and TACTIC.
I’m glad you got a little amusement by my mistake
Doc D
40% increase in hospital admissions is very concerning given most people are vaccinated and a tremendous burden on the health system. How many countries are actually counting now?
https://www.tbsnews.net/bangladesh/health/who-warns-covid-still-threat-773166?amp
“Besides the near 10,000 deaths reported to the WHO last month, there was a 42 percent increase in hospitalisations and a 62 percent increase in intensive care unit admissions, compared with November.
However, the figures are based on data from less than 50 countries -- mostly in Europe and the Americas, Tedros said.
"It is certain that there are also increases in other countries that are not being reported”
The interesting and somewhat scary read from this is most people are now vaccinated to some degree and yet a 40% increase in ICU
New treatments and less are dying but if you end up in ICU the long term consequences to your health and the ongoing cost to the health system or insurance can be vast.
“During the period from 11 December 2023 to 7 January 2024, COVID-19 new hospitalizations and admissions to an intensive care unit (ICU) both recorded an overall increase of 40% and 13% with over 173 000 and 1900 admissions, respectively”
Accelerated immune ageing is associated with COVID-19 disease severity
Doesn’t bode well for us as we get older
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782727/
“Whether or not this enhanced immunesenescence ( the state of dysregulated immune function that contributes to the increased susceptibility of the elderly to infection and possibly to autoimmune disease) is a result or consequence of COVID-19, it does suggest that these patients will be more vulnerable to future infections, show compromised vaccine responses and be at a higher risk of autoimmune disease. Moreover, as the induction of an aged immune system, specifically senescent CD4 T cells, has been shown in mice to be sufficient to drive an aged phenotype, including frailty and multimorbidity [46], our data may also suggest broader implications for the health of COVID-19 survivors. Evidence from recent studies has suggested the persistence of a spectrum of COVID-19 symptoms for up to 12 months after diagnosis, termed Long COVID, including persistent fatigue, myalgia and respiratory complications [47, 48]. Studies of COVID-19 convalescents 3–5 months post-infection have revealed maintained high levels of IL-6 associated with persistence of symptoms [4] and a study of autoantibody levels in serum found a high frequency of antibodies against the skin, skeletal muscle and cardiac tissue [5]. The aged immune system may thus contribute to both the acute and chronic sequelae of COVID-19”
WHO stats
Globally, the number of new cases increased by 4% during the 28-day period of 11 December 2023 to 7 January 2024 as compared to the previous 28-day period, with over 1.1 million new cases. The number of new deaths decreased by 26% as compared to the previous 28-day period, with 8700 new fatalities reported. As of 7 January 2024, over 774 million confirmed cases and over seven million deaths have been reported globally.
During the period from 11 December 2023 to 7 January 2024, COVID-19 new hospitalizations and admissions to an intensive care unit (ICU) both recorded an overall increase of 40% and 13% with over 173 000 and 1900 admissions, respectively.
One things stands out
“Lots of qualifications for this general population study - Paxlovid patients twice as likely to be vaccinated”
We know vaccination dramatically reduces your risk of hospitalisation. We also know that Pfizer abandoned its study of less severely acute patients because they couldn’t show a difference compared to placebo.
These retrospect studies have to be taken with a large grain of salt. As we saw with Molnupiravir which in a clinically controlled study showed no advantage compared to placebo of vaccinated patients. It’s notable that Pfizer has not gone on to run a clinical trial of vaccinated patients.
In terms of sng001 or any drug, the cost equation relates to the cost of treatment vs benefit if they hadn’t received the drug
Sanofi is a good example COPD trials but other exist
Dupixent COPD Phase 3 Trial Program
randomized, Phase 3, double-blind, Enrolling a total of 1,874 patients
Our COPD results are 109 patients
That’s roughly 3 times the size of Sprinter
How could we have run a trial of that size after Sprinter failed.
We couldn’t afford to run a trial of that size even before Sprinter
Facts are what this chat board needs not delusional posters
These are the COPD results from 2022 that Phil Monk presented in 2023
https://synairgen.ams3.digitaloceanspaces.com/IDWeek-2023-SG015-Poster-Final.pdf
As far as I’m aware Casanova do not manufacture, they’ve produced a patent for a device.
So somewhere out there is a company manufacturing a device using their patent and being authorised by the regulators for this purpose.
Casanova, if it is their patent being used will no doubt be highly interested in the outcome of the results, as they are in many immune related discoveries, but their profits will come from the licensing of this patent to a manufacturer not from Synairgen or J&J surely?
The aryl hydrocarbon receptor (AhR), is a signaling pathway with regards to inflammatory lung diseases therapeutic potential of targeting the AhR in regulating inflammation during acute and chronic respiratory diseases.
Asthma viral infections, exacerbations
To evaluate the therapeutic effect of IFN-β on virus-induced asthma exacerbations, we treated asthma exacerbation mice with IFN-β or dexamethasone (Dex)
IFN-β treatment was significantly more effective in preserving the respiratory system compliance and tissue damping and elasticity which indicates that IFN-β treatment not only has an effect on the airways, but also has a good effect of improvement on AHR caused by tissue damage
Asthma exacerbations lead to over 50,000 hospital admissions with an annual spend of £800 million on pharmaceutical costs alone. In addition, it is estimated that asthma leads to a direct cost to the NHS of £1 billion
https://www.nature.com/articles/s41467-023-44168-0
Seriously Mani you’re getting as bad as Doc D
Cut
Make it all up
Paste
We need a P3 eventually and don’t have the funds so no one has ever said we won’t eventually need to FJS d that in some way.
But we are not all screaming raise now at 5p for trials the company have already told us they can afford.
This isn’t the first time you’ve cried wolf
Get real and stop posting drivel
Doc D
There you go again with your
cut
Making things up
Paste
I’ve said what the company have said
Cut
The Company’s cash resources are sufficient to cover its plans to design and
establish data from an observational study and two investigator-led/Synairgen-
sponsored Phase 2 clinical trials, including manufacture of active and placebo
for use in these trials. Regardless of the outcome of these activities, which are
uncertain, the Company’s available resources are sufficient to cover existing
committed costs and the estimated costs of these activities until at least 30
September 2024
Paste
You really should take up a position in politics your mistruths are so believably well presented.